Sanofi and Regeneron's Dupixent Approved in Japan for Bullous Pemphigoid Treatment

Sanofi and Regeneron's Dupixent has been approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid, a chronic and relapsing skin disease with underlying type 2 inflammation. Approval was based on pivotal study results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo. BP affects elderly patients, causing intense itch, painful blisters, and lesions. Dupixent is also approved in Japan for certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic spontaneous urticaria, and chronic obstructive pulmonary disease.